<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412022000200119</article-id>
<article-id pub-id-type="doi">10.24245/gom.v90i2.7202</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Respuesta ovárica y tasa de nacido vivo en pacientes con cuenta folicular antral y hormona antimülleriana alteradas en ciclos de reproducción asistida]]></article-title>
<article-title xml:lang="en"><![CDATA[Ovarian response and LBR in patients with altered antral follicular count and anti- Müllerian hormone in assisted reproduction cycles.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández del Campo-Audelo]]></surname>
<given-names><![CDATA[Mayella]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barros-Delgadillo,]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muńoz-Manrique]]></surname>
<given-names><![CDATA[Cinthya]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Perinatología Isidro Espinosa de los Reyes  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Perinatología Isidro Espinosa de los Reyes  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Perinatología Isidro Espinosa de los Reyes  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<volume>90</volume>
<numero>2</numero>
<fpage>119</fpage>
<lpage>133</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412022000200119&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412022000200119&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412022000200119&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  OBJETIVO: Evaluar la relación entre la cuenta folicular antral y la hormona antimülleriana con la cantidad de ovocitos recuperados y la tasa de nacido vivo.  MATERIALES Y MÉTODOS:  Estudio retrospectivo, observacional, descriptivo y comparativo efectuado en pacientes atendidas en un hospital de tercer nivel. Parámetros de estudio: ciclos FIVTE-ICSI practicados entre enero de 2017 y marzo de 2021. Los ciclos, para fines de estudio, se dividieron en tres grupos: 1) cuenta folicular antral, 2) hormona antimülleriana y 3) ambos parámetros alterados. Para evaluar la relación de los marcadores con la cantidad de ovocitos recuperados y la tasa de nacido vivo se llevó a cabo un análisis estadístico exploratorio. Entre los tres grupos se compararon las características sociodemográficas y clínicas mediante las pruebas de Kruskal-Wallis y &#967;2, para variables continuas y categóricas, respectivamente. Se consideró significativo un nivel menor de 0.50; se utilizó el programa estadístico STATA 12.  RESULTADOS: Entre los tres grupos analizados se incluyeron 222 ciclos: con cuenta folicular antral, hormona antimülleriana o ambos alterados. Se encontraron 54 (24.3%) con un nacido vivo. La cantidad de folículos antrales y la tasa de nacido vivo fueron significativamente menores en las pacientes con ambos marcadores alterados. Las pacientes con concentraciones alteradas de hormona antimülleriana tuvieron mejor pronóstico (RM 2.3; IC95%: 1.08-4.93, p &lt; 0.03). La dosis de FSH y la cantidad de embriones transferidos fueron las variables que influyeron en la probabilidad de tener un recién nacido vivo.  CONCLUSIONES: La concentración de hormona antimülleriana menor de 1.2 ng/mL se relaciona con mejor respuesta ovárica y mayor tasa de nacido vivo. Esta mayor probabilidad está influida por la cantidad de gonadotropinas utilizada y de embriones transferidos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  OBJECTIVE: To evaluate the relationship between antral follicular count and antimüllerian hormone with the number of oocytes retrieved and live birth rate.  MATERIALS AND METHODS: Retrospective, observational, descriptive and comparative study carried out in patients attended at a tertiary level hospital. Study parameters: IVF-ICSI cycles performed between January 2017 and March 2021. The cycles, for study purposes, were divided into three groups: 1) antral follicular count, 2) antimüllerian hormone and 3) both parameters altered. To evaluate the relationship of the markers with the number of oocytes recovered and the live birth rate, an exploratory statistical analysis was performed. Sociodemographic and clinical characteristics were compared between the three groups using Kruskal-Wallis and 2 tests for continuous and categorical variables, respectively. A level of less than 0.50 was considered significant; STATA 12 statistical software was used.  RESULTS: Among the three groups analyzed, 222 cycles were included: with antral follicular count, antimüllerian hormone or both altered. Fifty-four (24.3%) were found with a live birth. The number of antral follicles and live birth rate were significantly lower in patients with both markers altered. Patients with altered antimüllerian hormone concentrations had better prognosis (MR 2.3; 95%CI: 1.08-4.93, p &lt; 0.03). FSH dose and number of embryos transferred were the variables that influenced the probability of having a live newborn.  CONCLUSIONS: Antimüllerian hormone concentration less than 1.2 ng/mL is related to better ovarian response and higher live birth rate. This higher probability is influenced by the number of gonadotropins used and embryos transferred.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[FIVTE-ICSI]]></kwd>
<kwd lng="en"><![CDATA[hormona antimülleriana]]></kwd>
<kwd lng="en"><![CDATA[tasa de nacido vivo]]></kwd>
<kwd lng="en"><![CDATA[respuesta ovárica]]></kwd>
<kwd lng="en"><![CDATA[gonadotropinas]]></kwd>
<kwd lng="en"><![CDATA[transferencia de embriones]]></kwd>
<kwd lng="es"><![CDATA[IVF-ICSI]]></kwd>
<kwd lng="es"><![CDATA[Antimüllerian hormone]]></kwd>
<kwd lng="es"><![CDATA[Live birth rate]]></kwd>
<kwd lng="es"><![CDATA[Ovarian response]]></kwd>
<kwd lng="es"><![CDATA[Gonadotropins]]></kwd>
<kwd lng="es"><![CDATA[Embryos transferred]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moolhuyjsen]]></surname>
<given-names><![CDATA[LME]]></given-names>
</name>
<name>
<surname><![CDATA[Visser]]></surname>
<given-names><![CDATA[JA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2020</year>
<volume>105</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3361-73</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<source><![CDATA[ACOG committee opinion 618 Ovarian Reserve Testing]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Washington, DC ]]></publisher-loc>
<publisher-name><![CDATA[American College of Obstetricians and Gynecologists]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Hodnett]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Knowlton]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Craig]]></surname>
<given-names><![CDATA[LB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlation of ovarian reserve tests with histologically determined primordial follicle number]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2011</year>
<volume>95</volume>
<page-range>170-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Seifer]]></surname>
<given-names><![CDATA[DB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ovarian reserve testing: a user&amp;apos;s guide]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2017</year>
<volume>217</volume>
<page-range>129-40</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Broer]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Dólleman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Opmeer]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Fauser]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis]]></article-title>
<source><![CDATA[Hum Reprod Update]]></source>
<year>2011</year>
<volume>17</volume>
<page-range>46-54</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vural]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cakiroglu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Vural]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Filiz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hormonal and functional biomarkers in ovarian response]]></article-title>
<source><![CDATA[Arch Gynecol Obstet]]></source>
<year>2014</year>
<volume>289</volume>
<page-range>1355-61</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferraretti]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[La Marca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fauser]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Tarlatzis]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of &amp;apos;poor response&amp;apos; to ovarian stimulation for in vitro fertilization: the Bologna criteria]]></article-title>
<source><![CDATA[Hum Reprod]]></source>
<year>2011</year>
<volume>26</volume>
<page-range>1616-24</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Humaidan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alviggi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Esteves]]></surname>
<given-names><![CDATA[SC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The novel POSEIDON stratification of &amp;apos;Low prognosis patients in Assisted Reproductive]]></article-title>
<source><![CDATA[Technology&amp;apos; and its proposed marker of successful outcome]]></source>
<year>2016</year>
<volume>5</volume>
<page-range>2911</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[La Marca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sighinolfi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Radi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Argento]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antimullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)]]></article-title>
<source><![CDATA[Hum Reprod Update]]></source>
<year>2010</year>
<volume>16</volume>
<page-range>113-30</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[EY]]></given-names>
</name>
<name>
<surname><![CDATA[Yeung]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>23</volume>
<page-range>8-e61095</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2015</year>
<volume>103</volume>
<page-range>e9-e17</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devine]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mumford]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[DeCherney]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181.536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2015</year>
<volume>104</volume>
<page-range>612-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Infertility Workup for the Women&amp;apos;s Health Specialist: ACOG Committee Opinion, Number 781]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2019</year>
<volume>133</volume>
<page-range>e377-84</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Shang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discordance between antral follicle counts and anti-Müllerian hormone levels in women undergoing in vitro fertilization]]></article-title>
<source><![CDATA[Reprod Biol Endocrinol]]></source>
<year>2019</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>51</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaegter]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Lakic]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Olovsson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berglund]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Which factors are most predictive for live birth after in vitro fertilization and intracytoplasmic sperm injection (IVF/ICSI) treatments? Analysis of 100 prospectively recorded variables in 8,400 IVF/ICSI single-embryo transfers]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2017</year>
<volume>107</volume>
<page-range>641-648.e2</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Xiong]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediction of in vitro fertilization outcome at different antral follicle count thresholds combined with female age, female cause of infertility, and ovarian response in a prospective cohort of 8269 women]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2019</year>
<volume>98</volume>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jayaprakasan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Islam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Haoula]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2012</year>
<volume>98</volume>
<page-range>657-63</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Luke]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2015</year>
<volume>104</volume>
<numero>1145-52e</numero>
<issue>1145-52e</issue>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[La Marca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sunkara]]></surname>
<given-names><![CDATA[SK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice]]></article-title>
<source><![CDATA[Hum Reprod Update]]></source>
<year>2014</year>
<volume>20</volume>
<page-range>124-40</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leijdekkers]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Torrance]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Schouten]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[van Tilborg]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Individualized ovarian stimulation in IVF/ICSI treatment: it is time to stop using high FSH doses in predicted low responders]]></article-title>
<source><![CDATA[Hum Reprod]]></source>
<year>2020</year>
<volume>35</volume>
<page-range>1954-63</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malchau]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Henningsen]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Forman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Loft]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cumulative live birth rate prognosis based on the number of aspirated oocytes in previous ART cycles]]></article-title>
<source><![CDATA[Hum Reprod]]></source>
<year>2019</year>
<volume>34</volume>
<page-range>171-80</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Practice Committee of the American Society for Reproductive Medicine; Blastocyst culture and transfer in clinically assisted reproduction: a committee opinion]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2018</year>
<volume>110</volume>
<page-range>1246-52</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Practice Committee of the American Society for Reproductive Medicine. Guidance on the limits to the number of embryos to transfer: a committee opinion]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2017</year>
<volume>107</volume>
<page-range>901-3</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Majumder]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gelbaya]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Laing]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nardo]]></surname>
<given-names><![CDATA[LG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos]]></article-title>
<source><![CDATA[Eur J Obstet Gynecol Reprod Biol]]></source>
<year>2010</year>
<volume>150</volume>
<page-range>166-70</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sunkara]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Rittenberg]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Raine-Fenning]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bhattacharya]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles]]></article-title>
<source><![CDATA[Hum Reprod]]></source>
<year>2011</year>
<volume>26</volume>
<page-range>1768-74</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pacheco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García Velasco]]></surname>
<given-names><![CDATA[JA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of very low anti-Müllerian hormone on pregnancy success]]></article-title>
<source><![CDATA[Curr Opin Obstet Gynecol]]></source>
<year>2017</year>
<volume>29</volume>
<page-range>131-5</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kedem]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Geva]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Yerushalmi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ongoing pregnancy rates in women with low and extremely low AMH levels. A multivariate analysis of 769 cycles]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>12</numero>
<issue>12</issue>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reichman]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Goldschlag]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenwaks]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Value of antimüllerian hormone as a prognostic indicator of in vitro fertilization outcome]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2014</year>
<volume>101</volume>
<page-range>1012-8.e1</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[EY]]></given-names>
</name>
<name>
<surname><![CDATA[Yeung]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ovarian response and cumulative live birth rate of women undergoing in-vitro fertilization who had discordant anti-Mullerian hormone and antral follicle count measurements: a retrospective study]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-Müllerian hormone and antral follicle count differ in their ability to predict cumulative treatment outcomes of the first complete ovarian stimulation cycle in patients from POSEIDON groups 3 and 4]]></article-title>
<source><![CDATA[J Obstet Gynaecol Res]]></source>
<year>2020</year>
<volume>46</volume>
<page-range>1801-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An elective single cleavage embryo transfer strategy to minimize twin live birth rate based on a prediction model from double cleavage embryos transfer patients]]></article-title>
<source><![CDATA[J Matern Fetal Neonatal Med]]></source>
<year>2020</year>
<volume>3</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
